Looking Toward the New Trends in CLL
Susan M. O’Brien, MD, on upcoming 2022 trends in chronic lymphocytic leukemia treatment.
EP: 1.Major Breakthroughs in Treating Chronic Lymphocytic Leukemia
EP: 2.Intriguing CLL Data From 2021 Conferences
EP: 3.Noncovalent BTK Inhibitors for Chronic Lymphocytic Leukemia
EP: 4.Approved BTK Inhibitors for Chronic Lymphocytic Leukemia
EP: 5.BTK Inhibitors in the Presence of 17p Deletions or TP53 Mutation in CLL
EP: 6.Combination Therapies for Chronic Lymphocytic Leukemia
EP: 7.Adverse Effects of Concern When Treating Chronic Lymphocytic Leukemia
EP: 8.Novel Mechanisms of Action in Chronic Lymphocytic Leukemia
EP: 9.Ongoing Trials of Combination Therapy for Treating CLL
EP: 10.Importance of Clinical Trial Enrollment for CLL
EP: 11.Looking Toward the New Trends in CLL
EP: 12.Potential Approvals of CLL Combination Therapies in 2022
Susan M. O’Brien, MD: What I’d like to see in 2022 is that at least 1 of the noncovalent inhibitors, if not both, get FDA approved. That would be very exciting. Right now, patients do need to go on a clinical trial, which is well worth their doing, but it would be nice [for those agents to be approve] because it wouldn’t be limited to clinical trials. Those 2 drugs are going to really give us a fabulous option that we don’t have now [for patients who] develop resistance to the first-generation BTK inhibitors. They appear to be amazingly nontoxic and that’s partly because, if you look at the KINOME assays, they’re very specific for BTK, particularly pirtobrutinib [LOXO-305]. Not only is it nice to have great efficacy, but it’s also nice to have very low toxicity. Those will change practice, and I’m hoping that we are going to see FDA approval of those drugs or at least 1 of them in 2022.
